[Monitoring of sE-selectin serum levels in three different dermatoses].
To determine the behaviour of serum levels of soluble E-selectin (sE-selectin), the soluble isoform of E-selectin, before/during/after therapy in patients with three. Using commercially available ELISA kits, serum levels of sE-selectin have been determined in 15 patients with psoriasis, 15 with pemphigus vulgaris and 15 with bullous pemphigoid, and compared with those of 30 healthy subjects. The results showed increased serum levels of sE-selectin in the three groups of patients as compared with those of 30 healthy subjects (p < 0.01). In addition, serum levels were significantly correlated with the disease activity expressed as Psoriasis Area and Severity Index (PASI score) (R = 0.56, p = 0.014) in psoriasis, and as number of the visible lesions (blisters/erosions), in the two bullous dermatoses (R = 0.81, p < 0.01). After therapy, the marker levels were significantly decreased (p < 0.01). Overall, these data suggest that serum determinations of sE-selectin could represent a clinically useful indicator to monitor therapy.